Family Heart Foundation Launches Innovative Program to Advance Screening of Lipoprotein(a), a Highly Underdiagnosed Genetic Risk
WASHINGTON , September 27 /Businesswire/ - The Family Heart Foundation, with support from Novartis, launched an innovative program that uses artificial intelligence to advance screening of elevated lipoprotein(a), a highly underdiagnosed genetic risk factor for premature cardiovascular disease.